Next Generation Sequencing (NGS) Market by Offering (Kits [Library Prep, QC, DNA Extraction], System) Type (Genome, Exome, Targeted) Application (Reproductive, Oncology, Infectious) Technology (SBS, Nanopore, Nanoball, SMRT Seq) – Global Forecast to 2030

Next Generation Sequencing (NGS) Market by Offering (Kits [Library Prep, QC, DNA Extraction], System) Type (Genome, Exome, Targeted) Application (Reproductive, Oncology, Infectious) Technology (SBS, Nanopore, Nanoball, SMRT Seq) – Global Forecast to 2030

The global NGS market is projected to reach $27.5 billion by 2030, at a CAGR of 15.8% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the NGS market is driven by rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory and reimbursement scenarios for NGS-based diagnostic tests.

However, the high costs of NGS systems and consumables, the availability of alternative technologies, the low chances of identifying positive, actionable mutations for precision medicine, and ethical and legal issues related to NGS-based diagnosis restrain the growth of this market. The increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to create growth opportunities for the players operating in the NGS market.

However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing are major challenges to market growth. The increasing demand for NGS automation, the development of portable sequencing technologies, and increasing partnerships and collaborations among NGS instrument manufacturers to expand and improve product offerings are prominent trends in the next-generation sequencing market.

Based on offering, in 2023, the consumables segment is expected to account for the largest share of the market. The growing adoption of NGS technology in research institutes, pharmaceutical and biotechnology companies, increasing adoption of NGS for genome mapping purposes, increasing the demand for consumables.

Based on sequencing type, targeted genome sequencing is expected to account for the largest share of the market. Targeted genome sequencing offers high throughput sequencing, high reliability, and low cost compared to WGS and WES, which are driving this segment's growth.

Based on technology, the sequencing by synthesis segment is expected to account for the largest share of the market. Less time for sequencing, error-free results, and low cost compared to other technologies are leading to the largest share of the segment. Additionally, the growing incorporation of this technology in NGS products further supports the largest share of this segment.

Based on application, in 2023, the clinical applications segment is expected to register the highest CAGR in the global NGS market. The increase in cancer cases, growing research activities to develop genome-based cancer medicine, and applications of NGS in reproductive health diagnosis contribute to this segment's large market share.

Based on end user, the hospitals and diagnostic laboratories segment is projected to register the highest CAGR during the forecast period. High patient inflows at hospitals and diagnostic laboratories, a wider range of services and treatments, and growing collaborations between hospitals and NGS supplier companies are supporting the growth of this segment.

An in-depth analysis of the geographical scenario of the global NGS market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the NGS market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The factors supporting the largest share of this market are technological advancements in the region, the increasing prevalence of cancer, and increased healthcare care spending. Additionally, the presence of key players, well-established healthcare infrastructure, and government initiatives for NGS-based diagnostic testing also contribute to the large market share of North America.

The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China).

Scope of the Report:


NGS Market Assessment, By Offering

Consumables
Sample Preparation Consumables
DNA Extraction and Amplification
Library Preparation & Target Enrichment
Quality Control
Other Consumables
NGS Platforms/Instruments
Software
Services

(Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes)

NGS Market Assessment, by Sequencing Type

Targeted Genome Sequencing
Whole Genome Sequencing
Whole Exome Sequencing
Other Sequencing Types

(Other sequencing types include degradome sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing)

NGS Market Assessment, by Technology

Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing (SMRT)
Nanopore Sequencing
DNA nanoball sequencing

(Other sequencing technologies include polony sequencing, sequencing by ligation, pyrosequencing, and true single molecule sequencing (tSMS))

NGS Market Assessment, by Application

Research Applications
Drug Discovery
Agriculture & Animal Research
Other Research Applications
Clinical Applications
Reproductive Health Diagnosis
Oncology
Infectious Diseases
Other Clinical Applications

(Other research applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies, and other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses)

NGS Market Assessment, by End User

Hospitals and Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Academic Institutes & Research Centers
Other End Users

(Other end users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies)

NGS Market Assessment, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
China
Japan
India
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATAM)
Middle East & Africa

Next-generation Sequencing (NGS) Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	317
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Sequencing Type, Technology, Application, and End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China).

FAQs About the ReportWhat is the focus of the NGS market?

The global NGS market is segmented by Offering (Consumables [Sample Preparation Consumables {DNA Extraction and Amplification, Library Preparation & Target Enrichment, Quality Control}, Other Consumables], NGS Platforms/Instruments, Software, Services), Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Other Sequencing Types), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), Nanopore Sequencing, DNA Nanoball Sequencing), Applications (Clinical Applications [Reproductive Health, Oncology, Infectious Diseases, Other Clinical Applications], Research and Other Applications [Drug Discovery, Agriculture & Animal Research, Other Research Applications), End User (Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic Institutes & Research Centers, Other End Users), and Geography. The global NGS market studied in this report involves the value analysis of various segments of NGS at regional and country levels.

What is the value of revenue generated from selling NGS across the globe?

The global NGS market is projected to reach $27.5 billion by 2030, at a CAGR of 15.8% during the forecast period.

Which NGS offering sub-segment is estimated to hold the major share of the market in 2023?

The consumables segment is estimated to account for the largest share of the NGS market in 2023. The recurring use of consumables, rising adoption of NGS by pharmaceutical and biotechnology companies, increasing cases of cancer and other chronic diseases and the rising cult of healthcare professionals for NGS-based tests for treatment purposes is increasing the use of consumables.

Which sequencing type segment is projected to create more demand in the global NGS market?

Based on the sequencing type, the targeted genome sequencing segment is projected to create more demand, owing to highly accurate results, increasing demand for targeted genome sequencing, and low cost with high reliability.

Which technology segment is projected to create more traction in the global NGS market?

Based on technology, the sequencing by synthesis segment is projected to create more traction during the forecast period due to the growing incorporation of this technology in NGS products, the highest yield of error-free throughput, and the high accuracy of this technology in DNA sequencing.

Which NGS application is estimated to hold the major share of the market in 2023?3

The research application segment is estimated to account for the largest share of the NGS market in 2023. Factors include increasing applications of NGS in treating chronic diseases such as cardiovascular diseases, cancer, and genetic diseases. The increase in genome mapping programs and the focus of key players on supporting affordable NGS instruments are responsible for the largest share of the segment.

Which end-user segment is projected to create more traction in the global NGS market?

Based on end user, the hospitals and diagnostic laboratories segment is projected to create more traction during the forecast period due to an increasing patient inflow in the hospital and diagnostic laboratories, more well-established infrastructure, and technological advancements.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global NGS market?

The growth of the global NGS market is attributed to the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory and reimbursement scenarios for NGS-based diagnostic tests.

Who are the major players operating in the global NGS market?

The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

The emerging Asian-Pacific countries are projected to offer significant growth opportunities for the vendors in this market due to the growing demand for NGS-based diagnostic tests, rising healthcare expenditure, increasing investments by healthcare providers towards infrastructure improvement, and growing accessibility of advanced healthcare services & products.